New data highlights include: - Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM hGH - Initial findings from research on comorbidities associated with ...
COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet ...
– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value 600 mg/day of calcium supplements) with no increase in prescribed ...
COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, ...
COPENHAGEN, Denmark, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under ...
COPENHAGEN, Denmark, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on ...
Copyright © 2015 - 2021 Lifecarenews.in
